Oligodendroglioma historical perspective: Difference between revisions

Jump to navigation Jump to search
 
(56 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Oligodendroglioma}}
{{Oligodendroglioma}}
{{CMG}}{{AE}}{{SR}}
{{CMG}}{{AE}}{{S.M.}}{{SR}}


==Overview==
==Overview==
Oligodendroglioma was first reported by W. E. Carnegie Dickson in 1926.<ref name="pmidhttp://dx.doi.org/10.1093/brain/49.4.578">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=http://dx.doi.org/10.1093/brain/49.4.578 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10  }} </ref> In 2009, Kevin Smith was the first to discover the association between ''[[mutation|NJDS]]'' mutation and irradiation of pituitary adenoma and development of oligodendroglioma.<ref name=history>Etiology of oligodendroglioma. Wikipedia. https://en.wikipedia.org/wiki/Oligodendroglioma</ref>
In 1926, the term "[[oligodendroglioma]]" was first coined by Bailey and Cushing, and was first described and published by W. E. Carnegie Dickson. [[Oligodendrogliomas]] were first [[Classification|classified]] and [[Grading (tumors)|graded]] in a [[system]] devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, [[classification]] and [[Grading (tumors)|grading]] of [[gliomas]] have [[evolved]] over the time. Modern [[World Health Organization|WHO]] [[classification]] of [[oligodendrogliomas]] was first published in 1979 and revised four times since then, with the most recent published in 2016. In 1997, a Westergaard's [[Study design|study]] showed that [[patients]] younger than 20 [[Year|years]] had a [[median]] [[Survival rate|survival]] of 17.5 years. In 2001, a [[Study design|study]] at [[Mayo Clinic]] was conducted to [[Assessment and Plan|assess]] the [[prognostic]] [[Value (mathematics)|value]] of [[histological]] [[Grading (tumors)|grading]] of [[Oligodendroglial tumor|oligodendroglial tumors]] in [[Grading (tumors)|tumor grading]] and [[Significant figure|significant]] [[Association (statistics)|association]] with [[Survival analysis|survival]] was found for [[age]], high [[Cellular|cellularity]], presence of [[mitoses]], [[endothelial]] [[hypertrophy]] and [[proliferation]] and [[necrosis]] on [[univariate]][[analysis]], but only [[age]] and presence of [[endothelial]] [[proliferation]] were found to be [[Independent assortment|independently]] [[Association (statistics)|associated]] with [[Survival rate|survival]] on a multivariable [[analysis]]. In 2009, ''[[Mutation|NJDS]]''[[mutation]] was first identified in the [[pathogenesis]] of [[oligodendroglioma]] by Kevin Smith. It was suggested in 2009 ASCO Annual Meeting that [[PCV regimen|PCV]] [[therapy]] may be [[superior]] in [[efficacy]] to the [[New|newer]] [[temozolomide]] [[therapy]]. [[Radiation|Irradiation]] of [[pituitary adenoma]] was also [[Discovery system|discovered]] to be [[Association (statistics)|associated]] with [[oligodendroglioma]] by Kevin Smith et al.


==Historical Perspective==
==Historical Perspective==
*Oligodendroglioma was first reported by W. E. Carnegie Dickson in 1926.<ref name="pmidhttp://dx.doi.org/10.1093/brain/49.4.578">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=http://dx.doi.org/10.1093/brain/49.4.578 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }} </ref>  
*The [[Term logic|term]] [[oligodendroglioma]] was [[derived]] from the [[Greek key|Greek]] words "''[[oligo]]''" [[Mean|meaning]] [[Fewmets|few]] and "''[[Dendrons|dendro]]''" [[Mean|meaning]] [[Treeshrew|trees]].
*In 2009, Kevin Smith was the first to discover the association between ''[[mutation|NJDS]]'' mutation and development of oligodendroglioma.<ref name=history>Etiology of oligodendroglioma. Wikipedia. https://en.wikipedia.org/wiki/Oligodendroglioma</ref>
*In 1926, the term "[[oligodendroglioma]]" was first coined by Bailey and Cushing  following the [[observation]] that the [[tumor]] [[Cells (biology)|cells]] are [[Morphological computation|morphologically]] similar to [[oligodendrocyte]]s.<ref name="pmid19322536">{{cite journal| author=Hartmann C, von Deimling A| title=Molecular pathology of oligodendroglial tumors. | journal=Recent Results Cancer Res | year= 2009 | volume= 171 | issue=  | pages= 25-49 | pmid=19322536 | doi=10.1007/978-3-540-31206-2_2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19322536  }} </ref>
*Their name derives from the Greek roots "''oligo''" meaning few and "''dendro''" meaning trees.
*In 1926, [[oligodendroglioma]] was first described and published by W. E. Carnegie Dickson.<ref name="drmet">{{Citation |last=Dickson |first=WEC|year=1926 |title=Proceeding of the Section of Neurology of the Royal Society Medicine: Oligodendroglioma of Floor of Third Ventricle |publisher=Brain-A journal of neurology |publication-place= |page=578 |url=http://brain.oxfordjournals.org/content/49/4/578 |accessdate= 11/20/2015}}</ref>
*In 1926, [[oligodendrogliomas]] were first [[Classification|classified]] and [[Grading (tumors)|graded]] in a [[system]] devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, [[classification]] and [[Grading (tumors)|grading]] of [[gliomas]] have [[evolved]] over the [[Time series|time]].
*In 1979, modern [[classification]] of [[gliomas]] [[Base|based]] on the [[World Health Organization]] ([[WHO]]) [[Classification]] of [[Central nervous system|Central Nervous System]] [[Tumors]] was first published and revised four times since then.
*In 1997, a Westergaard's [[Study design|study]] showed that [[patients]] younger than 20 [[Year|years]] had a [[median]] [[Survival analysis|survival]] of 17.5 [[Year|years]].<ref name="EngelhardStelea2003">{{cite journal|last1=Engelhard|first1=Herbert H|last2=Stelea|first2=Ana|last3=Mundt|first3=Arno|title=Oligodendroglioma and anaplastic oligodendroglioma:|journal=Surgical Neurology|volume=60|issue=5|year=2003|pages=443–456|issn=00903019|doi=10.1016/S0090-3019(03)00167-8}}</ref>
*In March 2001, 7 [[Neuropathologist|neuropathologists]] and 6 [[Surgery|surgical]] [[pathologists]] experienced in [[Brain tumor|brain tumor-]][[diagnosis]] [[Assessment and Plan|assessed]] 124 [[Oligodendroglial tumor|oligodendroglial tumors]] operated at the [[Mayo Clinic]] during the [[period]] of 1960 to 1990. In this [[Study design|study]], the [[prognostic]] [[Value (mathematics)|value]] of [[Histological grade|histological grading]] of [[Oligodendroglial tumor|oligodendroglial tumors]] in [[tumor]] [[Grading (tumors)|grading]] was [[Assessment and Plan|assessed]], and [[Significant figure|significant]] [[Association (statistics)|association]] with [[Survival analysis|survival]] was found for [[age]], high [[Cellular|cellularity]], presence of [[mitoses]], [[endothelial]] [[hypertrophy]] and [[proliferation]] and [[necrosis]] on [[univariate]] [[analysis]]. However, only [[age]] and presence of [[endothelial]] [[proliferation]] were found to be independently [[Association (statistics)|associated]] with [[Survival analysis|survival]] on a [[Multivariable calculus|multivariable]] [[analysis]].<ref name="pmid11245209">{{cite journal| author=Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S et al.| title=Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. | journal=J Neuropathol Exp Neurol | year= 2001 | volume= 60 | issue= 3 | pages= 248-62 | pmid=11245209 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11245209 }} </ref>
*In 2009 [[Oxford Forum|Oxford]] Neurosymposium study by Kevin Smith, it was first [[Discovery system|discovered]] that there is a 69% [[correlation]] between NJDS [[gene mutation]] and [[oligodendroglial tumor]] [[Initiation (chemistry)|initiation]].<ref name="history">Etiology of oligodendroglioma. Wikipedia. https://en.wikipedia.org/wiki/Oligodendroglioma</ref>
*In 2009 ASCO Annual Meeting, it was [[Suggestion|suggested]] that [[PCV regimen|PCV]] [[therapy]] may be [[superior]] in [[efficacy]] to the [[New|newer]] [[temozolomide]] [[therapy]]. This [[Study design|study]] showed that [[median]] [[Time-series|time]] to progression for [[patients]] with 1p19q co-deletion is longer following [[PCV regimen|PCV]] alone (7.6 [[Year|years]]) than with [[temozolomide]] alone (3.3 [[Year|years]]); [[median]] overall [[Survival analysis|survival]] is also longer with [[PCV regimen|PCV]] [[Treatments|treatment]] versus [[temozolomide]] [[Treatments|treatment]] (not reached, vs. 7.1 [[Year|years]]).<ref>{{cite journal|doi=10.1200/jco.2009.27.15s.2014}}</ref>
*Kevin Smith et al also [[Discovery system|discovered]] that [[radiation|irradiation]] of [[pituitary adenoma]] is [[Association (statistics)|associated]] with [[Precipitation (chemistry)|precipitation]] of [[oligodendroglioma]].
*In 2016 edition of the most recent [[World Health Organization|WHO]] [[classification]], [[gliomas]] are [[Classification|classified]] based not only on [[histopathologic]] [[appearance]] but also on well-established [[molecular]] [[Parameter|parameters]].


==References==
==References==
Line 22: Line 30:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Neurology]]
[[Category:Neurosurgery]]

Latest revision as of 14:01, 13 August 2019

Oligodendroglioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Oligodendroglioma from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Staging

History & Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Oligodendroglioma historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Oligodendroglioma historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Oligodendroglioma historical perspective

CDC on Oligodendroglioma historical perspective

Oligodendroglioma historical perspective in the news

Blogs on Oligodendroglioma historical perspective

Directions to Hospitals Treating Oligodendroglioma

Risk calculators and risk factors for Oligodendroglioma historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]

Overview

In 1926, the term "oligodendroglioma" was first coined by Bailey and Cushing, and was first described and published by W. E. Carnegie Dickson. Oligodendrogliomas were first classified and graded in a system devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, classification and grading of gliomas have evolved over the time. Modern WHO classification of oligodendrogliomas was first published in 1979 and revised four times since then, with the most recent published in 2016. In 1997, a Westergaard's study showed that patients younger than 20 years had a median survival of 17.5 years. In 2001, a study at Mayo Clinic was conducted to assess the prognostic value of histological grading of oligodendroglial tumors in tumor grading and significant association with survival was found for age, high cellularity, presence of mitoses, endothelial hypertrophy and proliferation and necrosis on univariateanalysis, but only age and presence of endothelial proliferation were found to be independently associated with survival on a multivariable analysis. In 2009, NJDSmutation was first identified in the pathogenesis of oligodendroglioma by Kevin Smith. It was suggested in 2009 ASCO Annual Meeting that PCV therapy may be superior in efficacy to the newer temozolomide therapy. Irradiation of pituitary adenoma was also discovered to be associated with oligodendroglioma by Kevin Smith et al.

Historical Perspective

References

  1. Hartmann C, von Deimling A (2009). "Molecular pathology of oligodendroglial tumors". Recent Results Cancer Res. 171: 25–49. doi:10.1007/978-3-540-31206-2_2. PMID 19322536.
  2. Dickson, WEC (1926), Proceeding of the Section of Neurology of the Royal Society Medicine: Oligodendroglioma of Floor of Third Ventricle, Brain-A journal of neurology, p. 578, retrieved 11/20/2015 Check date values in: |accessdate= (help)
  3. Engelhard, Herbert H; Stelea, Ana; Mundt, Arno (2003). "Oligodendroglioma and anaplastic oligodendroglioma:". Surgical Neurology. 60 (5): 443–456. doi:10.1016/S0090-3019(03)00167-8. ISSN 0090-3019.
  4. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S; et al. (2001). "Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading". J Neuropathol Exp Neurol. 60 (3): 248–62. PMID 11245209.
  5. Etiology of oligodendroglioma. Wikipedia. https://en.wikipedia.org/wiki/Oligodendroglioma
  6. . doi:10.1200/jco.2009.27.15s.2014. Missing or empty |title= (help)


Template:WikiDoc Sources